ATE500837T1 - Molekulare determinanten des multiplen myeloms und deren verwendung - Google Patents

Molekulare determinanten des multiplen myeloms und deren verwendung

Info

Publication number
ATE500837T1
ATE500837T1 AT07118621T AT07118621T ATE500837T1 AT E500837 T1 ATE500837 T1 AT E500837T1 AT 07118621 T AT07118621 T AT 07118621T AT 07118621 T AT07118621 T AT 07118621T AT E500837 T1 ATE500837 T1 AT E500837T1
Authority
AT
Austria
Prior art keywords
multiple myeloma
lytic
lesions
bone
bone disease
Prior art date
Application number
AT07118621T
Other languages
English (en)
Inventor
John Shaughnessy
Original Assignee
Univ Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Arkansas filed Critical Univ Arkansas
Application granted granted Critical
Publication of ATE500837T1 publication Critical patent/ATE500837T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
AT07118621T 2002-12-05 2003-12-04 Molekulare determinanten des multiplen myeloms und deren verwendung ATE500837T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US43104002P 2002-12-05 2002-12-05

Publications (1)

Publication Number Publication Date
ATE500837T1 true ATE500837T1 (de) 2011-03-15

Family

ID=32507666

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07118621T ATE500837T1 (de) 2002-12-05 2003-12-04 Molekulare determinanten des multiplen myeloms und deren verwendung

Country Status (11)

Country Link
US (1) US7459437B2 (de)
EP (2) EP1913952B1 (de)
JP (2) JP4874549B2 (de)
AT (1) ATE500837T1 (de)
AU (1) AU2003302926A1 (de)
CA (1) CA2507496C (de)
DE (1) DE60336356D1 (de)
ES (1) ES2362681T3 (de)
MX (1) MXPA05006033A (de)
PT (1) PT1913952E (de)
WO (1) WO2004053063A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7811750B2 (en) * 2002-12-05 2010-10-12 Board Of Trustees Of The University Of Arkansas Molecular determinants of myeloma bone disease and use thereof
WO2005070448A2 (en) * 2004-01-21 2005-08-04 Five Prime Therapeutics, Inc. Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease
CA2574881C (en) * 2004-08-04 2013-01-08 Amgen Inc. Antibodies to dkk-1
WO2006061430A2 (en) * 2004-12-10 2006-06-15 Proskelia Bone metastasis markers as a target regulating bone metastasis and bone development
JP2006217844A (ja) * 2005-02-09 2006-08-24 Univ Of Tokyo Ｄｋｋ１の遺伝子、蛋白質及び抗体を用いた癌の診断・モニター方法及び治療方法
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
CN101517096B (zh) 2006-03-13 2013-10-16 上海市肿瘤研究所 Dkk-1蛋白在癌症诊断中的应用
WO2009132815A1 (en) 2008-04-30 2009-11-05 Roche Diagnostics Gmbh Use of sfrp-3 in the assessment of heart failure
AR076668A1 (es) 2009-05-12 2011-06-29 Pfizer Anticuerpos especificos para dkk-1 y sus usos
CA2800018C (en) * 2010-05-21 2021-09-28 Universitaet Fuer Bodenkultur Wien Compositions for use in treating or diagnosing bone disorders and/or cardiovascular disorders
ES2624981T3 (es) 2011-07-01 2017-07-18 Dana-Farber Cancer Institute, Inc. Descubrimiento de una mutación somática en el gen MYD88 en linfoma linfoplasmocitario
WO2013010074A1 (en) 2011-07-13 2013-01-17 Primeradx, Inc. Multimodal methods for simultaneous detection and quantification of multiple nucleic acids in a sample
CA3206628A1 (en) 2013-09-12 2015-03-19 Dana-Farber Cancer Institute, Inc. Methods for evaluating and treating waldenstrom's macroglobulinemia
US10612095B2 (en) 2013-12-06 2020-04-07 Dana-Farber Cancer Institute, Inc. Methods to distinguish Waldenström's Macroglobulinemia from IgM monoclonal gammopathy of undetermined significance
JP6879740B2 (ja) 2013-12-13 2021-06-02 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド リンパ形質細胞性リンパ腫を処置する方法
WO2017189999A1 (en) 2016-04-29 2017-11-02 Dana-Farber Cancer Institute, Inc. Hck as a therapeutic target in myd88 mutated diseases
KR20220098732A (ko) 2019-10-08 2022-07-12 다나-파버 캔서 인스티튜트 인크. 요법, 특히 myd88 돌연변이된 질환에 사용하기 위한 hck 억제제로서의 피라졸로피리미딘 유도체

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3510200A (en) * 1999-03-05 2000-09-21 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
BR0014183A (pt) * 1999-09-13 2002-05-14 American Home Pruducts Corp Composições farmaceuticas e metodos de uso de proteìna relacionada frizzled secretada
US20040038860A1 (en) 2002-05-17 2004-02-26 Allen Kristina M. Reagents and methods for modulating dkk-mediated interactions
EP1395285A4 (de) * 2001-05-17 2005-06-01 Genome Therapeutics Corp Reagenzien und verfahren zur modulation von dkk-vermittelten wechselwirkungen

Also Published As

Publication number Publication date
WO2004053063A3 (en) 2004-11-25
CA2507496C (en) 2014-11-04
MXPA05006033A (es) 2006-03-08
CA2507496A1 (en) 2004-06-24
US20040137489A1 (en) 2004-07-15
JP5432966B2 (ja) 2014-03-05
JP4874549B2 (ja) 2012-02-15
JP2012046535A (ja) 2012-03-08
EP1913952B1 (de) 2011-03-09
AU2003302926A1 (en) 2004-06-30
WO2004053063A2 (en) 2004-06-24
EP1567663A4 (de) 2006-04-19
EP1913952A1 (de) 2008-04-23
PT1913952E (pt) 2011-04-14
DE60336356D1 (de) 2011-04-21
ES2362681T3 (es) 2011-07-11
AU2003302926A8 (en) 2004-06-30
US7459437B2 (en) 2008-12-02
EP1567663A2 (de) 2005-08-31
JP2006512911A (ja) 2006-04-20

Similar Documents

Publication Publication Date Title
DE60336356D1 (de) Molekulare Determinanten des multiplen Myeloms und deren Verwendung
Cicuttini et al. Genetics of osteoarthritis.
Acevedo et al. Variability of systemic and oro-dental phenotype in two families with non-lethal Raine syndrome with FAM20C mutations
Tiziani et al. The gene for cherubism maps to chromosome 4p16
CN1471412B8 (zh) 用于修复和再生软骨和其它组织的组合物以及该组合物的用途
DE50306850D1 (de) Benzodiazepin-substituierte piperdine zur verwendung in der behandlung von cardiovaskulären erkrankungen
Flinter et al. Localization of the gene for classic Alport syndrome
DE60112807D1 (de) Zusammensetzung zur behandlung von durch arterielle irrigationsdefekt gewebeschäden
Noto et al. Dyskeratosis congenita associated with leukoplakia of the tongue
Frisk et al. Goltz syndrome in males: A clinical report of a male patient carrying a novel PORCN variant and a review of the literature
White et al. Kindler surprise: mutations in a novel actin-associated protein cause Kindler syndrome
Ebersole et al. Comparative analysis of gene expression patterns for oral epithelium-related functions with aging
Raza et al. A novel homozygous nonsense mutation in the PVRL4 gene and expansion of clinical spectrum of EDSS1
Hsiao et al. Matrix metalloproteinase-2,-9, and tissue inhibitor of MMP-2 gene polymorphisms in Taiwanese periodontitis patients
Gollasch et al. Identification of a novel mutation in RIPK4 in a kindred with phenotypic features of Bartsocas‐Papas and CHAND syndromes
Van Pham Tissue engineering and regenerative medicine
Colletti et al. Epidermal nevus and ameloblastoma: a rare association
Luo et al. Association of COL1A1 polymorphism with subchondral bone degeneration of the temporomandibular joint
Avcin et al. Early-onset osteoarthritis due to otospondylomegaepiphyseal dysplasia in a family with a novel splicing mutation of the COL11A2 gene.
Broker et al. Clinical aspects and polymorphisms in the LTA, TNFA, LTB genes and association with dental implant loss
Mohanan et al. Assessment of Salivary Flow Rate and Antioxidant Levels in Ectodermal Dysplasia Patients: An: In vivo: Study
Mohammadi-Asl et al. A novel pathogenic variant in the FZD6 gene causes recessive nail dysplasia in a large Iranian kindred
Shehzad et al. Detection of single nucleotide polymorphism rs2013162 of IRF6 gene in patient with cleft lip and palate
Quarnstrom et al. Repairing fractured porcelain-fused-to-metal bridge pontics
Sabesan et al. Dyskeratosis congenita: its connections with oral and maxillofacial surgery

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1913952

Country of ref document: EP